- Home
- HUDI vs BIVI Comparison
HUDI vs BIVI Comparison
Compare HUDI & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HUDI
- BIVI
- Stock Information
- Founded
- HUDI 2018
- BIVI 2013
- Country
- HUDI China
- BIVI United States
- Employees
- HUDI N/A
- BIVI N/A
- Industry
- HUDI Steel/Iron Ore
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- HUDI Industrials
- BIVI Health Care
- Exchange
- HUDI Nasdaq
- BIVI Nasdaq
- Market Cap
- HUDI 18.8M
- BIVI 18.6M
- IPO Year
- HUDI 2021
- BIVI N/A
- Fundamental
- Price
- HUDI $1.45
- BIVI $1.08
- Analyst Decision
- HUDI
- BIVI Strong Buy
- Analyst Count
- HUDI 0
- BIVI 1
- Target Price
- HUDI N/A
- BIVI $30.00
- AVG Volume (30 Days)
- HUDI 22.4K
- BIVI 282.1K
- Earning Date
- HUDI 06-13-2025
- BIVI 05-12-2025
- Dividend Yield
- HUDI N/A
- BIVI N/A
- EPS Growth
- HUDI N/A
- BIVI N/A
- EPS
- HUDI 0.01
- BIVI N/A
- Revenue
- HUDI $74,270,429.00
- BIVI N/A
- Revenue This Year
- HUDI N/A
- BIVI N/A
- Revenue Next Year
- HUDI N/A
- BIVI N/A
- P/E Ratio
- HUDI $149.59
- BIVI N/A
- Revenue Growth
- HUDI N/A
- BIVI N/A
- 52 Week Low
- HUDI $1.26
- BIVI $0.62
- 52 Week High
- HUDI $3.45
- BIVI $7.50
- Technical
- Relative Strength Index (RSI)
- HUDI 50.14
- BIVI 53.42
- Support Level
- HUDI $1.40
- BIVI $1.07
- Resistance Level
- HUDI $1.50
- BIVI $1.13
- Average True Range (ATR)
- HUDI 0.13
- BIVI 0.06
- MACD
- HUDI -0.00
- BIVI 0.00
- Stochastic Oscillator
- HUDI 16.67
- BIVI 65.99
About HUDI Huadi International Group Co. Ltd.
Huadi International Group Co Ltd is a manufacturer of industrial stainless steel seamless pipes and tubes products. Its products are used in the oil & gas transmission, chemistry engineering, food processing, medical devices, aeronautics and astronautics, boiler, irrigation works construction, automobile and naval architecture, paper mill and mechanical industries. Company generates revenue from Sales of steel piping products. Products are exported to the United States, Mexico, Thailand, Singapore, Argentina, Taiwan, India, the Philippines, UAE and Canada. Geographically, majority revenue is generated from China.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.